BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19
Status:
Completed
Trial end date:
2021-01-08
Target enrollment:
Participant gender:
Summary
According to WHO (World Health Organisation) data, about 40% of patients with COVID-19
(Corona Virus SARS-CoV-2) have a mild course of the disease, namely, cases of mild course are
of great danger from the point of view of the spread of infection, since the main source of
infection is a sick person. The mild course of COVID-19 is characterized by a number of
nonspecific symptoms: fever, cough, sore throat, nasal congestion, malaise, headache, muscle
pain. Evidence has emerged of loss of smell as a symptom of COVID-19 infection.
Anosmia/hyposmia in the absence of other respiratory diseases, such as allergic rhinitis,
acute rhinosinusitis, or chronic rhinosinusitis, are considered as a clinical marker of
COVID-19 infection in a pandemic.For people with a mild course of the disease, WHO recommends
providing home care, and the recommendations come down to observing a sanitary-hygienic
regimen and taking antipyretics if necessary. Unfortunately, the treatment of patients with a
mild course is still outside the interest of medical science. In its updated strategy to curb
the spread of COVID-19, WHO states the need for diagnosis, effective isolation, and treatment
of patients with mild to moderate severity of the clinical course of patients.Currently,
there is experience with the use of the drug Imupret for the treatment of nasopharyngitis
associated with other viral pathogens, in particular Epstein-Barr virus. It was shown that
the use of a Phyto preparation helps to accelerate the regression of symptoms characteristic
of nasopharyngitis, as well as accelerate the elimination of the virus from the body.
Obviously, the proven activity of Imupret is important in relation to the activation of
factors of nonspecific immunity, which is important in confronting viruses, including
COVID-19. Another obvious factor that is important for the treatment of viral diseases is the
synergism of the active substances in oak bark and walnut leaves with respect to inhibition
of reverse transcriptase of a wide range of respiratory viruses, as well as the
anti-inflammatory effect of the drug. Confirmation of the therapeutic effect of Imupret for
the treatment of nasopharyngitis associated with COVID-19 would allow the development of new
therapeutic tools to combat this infection and put into practice updated WHO emphasis on
national health systems: it is important to identify, treat and isolate all cases of
COVID-19, including cases with mild or moderate severity of the disease.